title: Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12.
abstract: An increased plasma homocysteine concentration is a risk factor for atherosclerosis. Folic acid lowers homocysteine but the optimal dose in patients with coronary artery disease (CAD) is unclear. This placebo-controlled, single-blind, dose-ranging study evaluates the effect of low-dose folic acid on homocysteine levels in 95 patients aged 61 +/- 11 years (mean +/- SD) with documented CAD. Patients in each group were given either placebo or 1 of 3 daily supplements of folic acid (400 microg, 1 mg, or 5 mg) for 3 months. Each active treatment arm also received 500 microg vitamin B12 and 12.5 mg vitamin B6. Total plasma homocysteine levels were measured after 30 and 90 days. Folic acid 400 microg reduced homocysteine levels from 13.8 +/- 8.8 to 9.6 +/- 2.0 micromol/L at 90 days (p = 0.001). On 1- and 5-mg folic acid, levels decreased from 13.0 +/- 6.4 to 9.8 +/- 4.0 micromol/L (p = 0.001) and from 14.8 +/- 6.9 to 9.7 +/- 3.3 micromol/L (p < 0.001), respectively. The decrease was similar in all treatment groups. There was no significant change with placebo. Although the sample size is small, these findings suggest that daily administration of 400 microg/day folic acid combined with vitamin B12 and vitamin B6 may be equivalent to higher doses in reducing homocysteine levels in patients with CAD.
authors: Department of Cardiology, The Cleveland Clinic Foundation, Ohio 44195, USA.
authors: A
authors: A
authors: Lobo
authors: A
authors: A
authors: Naso
authors: K
authors: K
authors: Arheart
authors: W D
authors: WD
authors: Kruger
authors: T
authors: T
authors: Abou-Ghazala
authors: F
authors: F
authors: Alsous
authors: M
authors: M
authors: Nahlawi
authors: A
authors: A
authors: Gupta
authors: A
authors: A
authors: Moustapha
authors: F
authors: F
authors: van Lente
authors: D W
authors: DW
authors: Jacobsen
authors: K
authors: K
authors: Robinson
mesh_terms: D003327:Coronary Disease / Q000097:blood* / Q000235:genetics; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage*; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008875:Middle Aged; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000097:blood / Q000235:genetics; D011110:Polymorphism, Genetic; D011736:Pyridoxine / Q000008:administration & dosage*; D016037:Single-Blind Method; D014805:Vitamin B 12 / Q000008:administration & dosage*
chemical_list: D006710:Homocysteine; D005492:Folic Acid; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D011736:Pyridoxine; D014805:Vitamin B 12